GlassScriptPhysician profile
Evan J Abramsky
NPI 1356319362
$9,778.24
in general payments reported to CMS, 2019-2025
30 companies · $1,848 in 2025
The $1,848 reported for 2025 was more than what 92% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,128 · 2022: $2,207 · 2023: $1,876 · 2024: $1,720 · 2025: $1,848.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,444.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,443.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $2,545.64 | 2021-2025 | Cimzia, Bimzelx |
| Amgen INC. | $1,255.58 | 2021-2025 | Evenity, Prolia, Krystexxa |
| E.R. Squibb & Sons, L.L.C. | $828.45 | 2021-2025 | Orencia |
| Astrazeneca Pharmaceuticals LP | $741.26 | 2022-2025 | Saphnelo |
| Janssen Biotech, INC. | $673.70 | 2021-2025 | Tremfya |
| Abbvie INC. | $623.26 | 2021-2025 | Skyrizi, Rinvoq |
| Novartis Pharmaceuticals Corporation | $611.52 | 2022-2025 | |
| Pfizer INC. | $452.41 | 2021-2025 | |
| Radius Health, INC. | $359.18 | 2021-2025 | Tymlos |
| Janssen Scientific Affairs, LLC | $236.66 | 2021-2022 | |
| Ani Pharmaceuticals, INC. | $214.09 | 2024-2025 | Purified Cortrophin Gel |
| Horizon Therapeutics Plc | $160.54 | 2021-2023 | Krystexxa |
| Mallinckrodt Hospital Products INC. | $146.54 | 2021 | |
| Lilly USA, LLC | $114.23 | 2021-2024 | Taltz |
| Scilex Pharmaceuticals INC. | $112.56 | 2024 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Therapeutics, INC. | $107.75 | 2021 | |
| Depuy Synthes Sales INC. | $106.73 | 2022-2025 | Monovisc, Orthovisc |
| Genentech USA, INC. | $64.76 | 2024-2025 | Actemra |
| Organon LLC | $62.72 | 2021-2025 | Renflexis, Hadlima |
| Pacira Pharmaceuticals Incorporated | $55.88 | 2023-2024 | Zilretta, Iovera, Exparel |
| Glaxosmithkline, LLC. | $51.06 | 2023-2025 | Benlysta |
| Sobi, INC | $45.77 | 2021-2025 | |
| Fresenius Kabi USA, LLC | $40.80 | 2025 | |
| Bioventus LLC | $39.68 | 2022-2024 | Supartz Fx Sodium Hyaluronate |
| Aurinia Pharma U.S., INC. | $24.28 | 2025 | Lupkynis |
| Alvogen INC | $23.77 | 2025 | Teriparatide |
| Grt US Holding, INC. | $23.07 | 2022 | |
| Endo USA, INC. | $20.81 | 2025 | Xiaflex |
| Zimmer Biomet Holdings, INC. | $19.75 | 2022 | |
| Alexion Pharmaceuticals, INC. | $15.79 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Evan Abramsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.